203 related articles for article (PubMed ID: 23593453)
1. Evaluation of an intranasal virosomal vaccine against respiratory syncytial virus in mice: effect of TLR2 and NOD2 ligands on induction of systemic and mucosal immune responses.
Shafique M; Meijerhof T; Wilschut J; de Haan A
PLoS One; 2013; 8(4):e61287. PubMed ID: 23593453
[TBL] [Abstract][Full Text] [Related]
2. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
Shafique M; Wilschut J; de Haan A
Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of an intranasal virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice and cotton rats.
Kamphuis T; Shafique M; Meijerhof T; Stegmann T; Wilschut J; de Haan A
Vaccine; 2013 Apr; 31(17):2169-76. PubMed ID: 23499594
[TBL] [Abstract][Full Text] [Related]
4. A virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A provides protection against viral challenge without priming for enhanced disease in cotton rats.
Kamphuis T; Stegmann T; Meijerhof T; Wilschut J; de Haan A
Influenza Other Respir Viruses; 2013 Nov; 7(6):1227-36. PubMed ID: 23575113
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and protective capacity of a virosomal respiratory syncytial virus vaccine adjuvanted with monophosphoryl lipid A in mice.
Kamphuis T; Meijerhof T; Stegmann T; Lederhofer J; Wilschut J; de Haan A
PLoS One; 2012; 7(5):e36812. PubMed ID: 22590614
[TBL] [Abstract][Full Text] [Related]
6. Influenza virosomes are an efficient delivery system for respiratory syncytial virus-F antigen inducing humoral and cell-mediated immunity.
Cusi MG; Zurbriggen R; Correale P; Valassina M; Terrosi C; Pergola L; Valensin PE; Glück R
Vaccine; 2002 Oct; 20(29-30):3436-42. PubMed ID: 12297388
[TBL] [Abstract][Full Text] [Related]
7. Development of a Virosomal RSV Vaccine Containing 3D-PHAD® Adjuvant: Formulation, Composition, and Long-Term Stability.
Lederhofer J; van Lent J; Bhoelan F; Karneva Z; de Haan A; Wilschut JC; Stegmann T
Pharm Res; 2018 Jul; 35(9):172. PubMed ID: 29971500
[TBL] [Abstract][Full Text] [Related]
8. Cutting edge: New chimeric NOD2/TLR2 adjuvant drastically increases vaccine immunogenicity.
Pavot V; Rochereau N; Rességuier J; Gutjahr A; Genin C; Tiraby G; Perouzel E; Lioux T; Vernejoul F; Verrier B; Paul S
J Immunol; 2014 Dec; 193(12):5781-5. PubMed ID: 25392526
[TBL] [Abstract][Full Text] [Related]
9. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of mucosal and systemic immune responses elicited by GPI-0100- adjuvanted influenza vaccine delivered by different immunization strategies.
Liu H; Patil HP; de Vries-Idema J; Wilschut J; Huckriede A
PLoS One; 2013; 8(7):e69649. PubMed ID: 23936066
[TBL] [Abstract][Full Text] [Related]
11. Nasal immunization with RSV F and G protein fragments conjugated to an M cell-targeting ligand induces an enhanced immune response and protection against RSV infection.
Khan IU; Huang J; Li X; Xie J; Zhu N
Antiviral Res; 2018 Nov; 159():95-103. PubMed ID: 30290196
[TBL] [Abstract][Full Text] [Related]
12. A novel respiratory syncytial virus (RSV) F subunit vaccine adjuvanted with GLA-SE elicits robust protective TH1-type humoral and cellular immunity in rodent models.
Lambert SL; Aslam S; Stillman E; MacPhail M; Nelson C; Ro B; Sweetwood R; Lei YM; Woo JC; Tang RS
PLoS One; 2015; 10(3):e0119509. PubMed ID: 25793508
[TBL] [Abstract][Full Text] [Related]
13. Signaling via pattern recognition receptors NOD2 and TLR2 contributes to immunomodulatory control of lethal pneumovirus infection.
Rice TA; Brenner TA; Percopo CM; Ma M; Keicher JD; Domachowske JB; Rosenberg HF
Antiviral Res; 2016 Aug; 132():131-40. PubMed ID: 27312104
[TBL] [Abstract][Full Text] [Related]
14. Formulation of the respiratory syncytial virus fusion protein with a polymer-based combination adjuvant promotes transient and local innate immune responses and leads to improved adaptive immunity.
Sarkar I; Garg R; van Drunen Littel-van den Hurk S
Vaccine; 2016 Sep; 34(42):5114-5124. PubMed ID: 27591951
[TBL] [Abstract][Full Text] [Related]
15. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
[TBL] [Abstract][Full Text] [Related]
16. Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation.
Stegmann T; Kamphuis T; Meijerhof T; Goud E; de Haan A; Wilschut J
Vaccine; 2010 Aug; 28(34):5543-50. PubMed ID: 20600502
[TBL] [Abstract][Full Text] [Related]
17. Incorporation of LpxL1, a detoxified lipopolysaccharide adjuvant, in influenza H5N1 virosomes increases vaccine immunogenicity.
de Vries JJ; Bungener L; Ter Veer W; van Alphen L; van der Ley P; Wilschut J; Huckriede A
Vaccine; 2009 Feb; 27(6):947-55. PubMed ID: 19059296
[TBL] [Abstract][Full Text] [Related]
18. Matrix-M adjuvanted virosomal H5N1 vaccine confers protection against lethal viral challenge in a murine model.
Pedersen G; Major D; Roseby S; Wood J; Madhun AS; Cox RJ
Influenza Other Respir Viruses; 2011 Nov; 5(6):426-37. PubMed ID: 21668670
[TBL] [Abstract][Full Text] [Related]
19. Single mucosal immunization of recombinant adenovirus-based vaccine expressing F1 protein fragment induces protective mucosal immunity against respiratory syncytial virus infection.
Kim S; Jang JE; Yu JR; Chang J
Vaccine; 2010 May; 28(22):3801-8. PubMed ID: 20362203
[TBL] [Abstract][Full Text] [Related]
20. Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.
O'Konek JJ; Makidon PE; Landers JJ; Cao Z; Malinczak CA; Pannu J; Sun J; Bitko V; Ciotti S; Hamouda T; Wojcinski ZW; Lukacs NW; Fattom A; Baker JR
Hum Vaccin Immunother; 2015; 11(12):2904-12. PubMed ID: 26307915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
